ArticleJournal of ophthalmic & vision research2011
Biologic agents in inflammatory eye disease.
Article in Journal of ophthalmic & vision research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- What Do Patients Know About Orthobiologics? Perceived Efficacy, Safety, and Factors Influencing Treatment Decisions.Orthopaedic journal of sports medicine · 2026Article
- Real-world landscape of drug-related ocular injuries: a retrospective pharmacovigilance study.Frontiers in pharmacology · 2026Article
- Ophthalmological manifestations in autoimmune diseases: Overcoming diagnostic and therapeutic challenges.World journal of experimental medicine · 2025Review
- A Comprehensive Immunocapture-LC-MS/MS Bioanalytical Approach in Support of a Biotherapeutic Ocular PK Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Combined central retinal vein occlusion and cilioretinal artery occlusion as the initial presentation of frosted branch angiitis: a case report and literature review.Journal of ophthalmic inflammation and infection · 2023Article
- Recombinant Human Clusterin Seals Damage to the Ocular Surface Barrier in a Mouse Model of Ophthalmic Preservative-Induced Epitheliopathy.International journal of molecular sciences · 2023Article
- Clusterin, other extracellular chaperones, and eye disease.Progress in retinal and eye research · 2022Review
- Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center.Clinical rheumatology · 2019Article
- Toll-like receptors 4, 5, 6 and 7 are constitutively expressed in non-human primate retinal neurons.Journal of neuroimmunology · 2018Article
- Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease.American journal of ophthalmology case reports · 2018Article
- Recent perspectives on the delivery of biologics to back of the eye.Expert opinion on drug delivery · 2017Review
- Biologic agents in experimental autoimmune uveitis.International ophthalmology · 2014Review
- Medical management of uveitis - current trends.Indian journal of ophthalmology · 2013Review
- JOVR is Promoting Closer Academic and Scientific Ties between Europe and Iran.Journal of ophthalmic & vision research · 2011Article
- Aqueous Humor Levels of Different Interleukins 1-β, 2, 6 and 10, Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab.Journal of ophthalmic & vision researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-infectious uveitis is a potentially sight threatening disease. Along the years, several therapeutic strategies have been proposed as a means to its treatment, including local and systemic steroids, immunosuppressives and more recently, biologic agents. The introduction of biologics can be defined as a new era: biologic therapies provide new options for patients with refractory and sight threatening inflammatory disorders. The availability of such novel treatment modalities has markedly improved the therapy of uveitis and considerably increased the possibility of long-term remissions. This article provides a review of current literature on biologic agents, such as tumor necrosis factor blockers, anti-interleukins and other related biologics, such as interferon alpha, for the treatment of uveitis. Several reports describe the efficacy of biologics in controlling a large number of refractory uveitides, suggesting a central role in managing ocular inflammatory diseases. However, there is still lack of randomized controlled trials to validate most of their applications. Biologics are promising drugs for the treatment of uveitis, showing a favorable safety and efficacy profile. On the other hand, lack of evidence from randomized controlled studies limits our understanding as to when commence treatment, which agent to choose, and how long to continue therapy. In addition, high cost and the potential for serious and unpredictable complications have very often limited their use in uveitis refractory to traditional immunosuppressive therapy.
Indexed as
Identifiers
22454752PMC3306110W2144023104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.